Metformin may shield aging muscles from inactivity
NCT ID NCT03107884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether metformin, a widely used diabetes drug, can prevent muscle loss and insulin resistance in healthy older adults during five days of bed rest. Researchers will measure changes in muscle size and insulin sensitivity. The study involves 64 participants aged 60 and older at the University of Utah.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Metformin (an oral diabetes drug)
- What this could lead to
- If it works, this could point toward a way to protect muscle health in older adults during periods of inactivity, like bed rest.
- What could go wrong
- This is a very small, early-phase study (64 people) testing a short-term effect. Results may not apply to real-world aging or long-term use, and metformin can cause stomach upset.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
64 people
The number who actually took part.
- Started
-
Aug 2019
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 60y and older * Ability to sign informed consent * Free-living, prior to admission Exclusion Criteria: * Personal history of cardiovascular disease * Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, HbA1c ≥6.5%) * Evidence of kidney disease or failure (defined as serum creatinine \> 1.5mg/dL) * Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, diabetes) * Risk of Deep vein thrombosis including family history of thrombophilia, Deep vein thrombosis, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\>18 g/dL) or thrombocytosis (platelets\>400x103/mL) * Use of anticoagulant therapy (e.g., Coumadin, heparin) * Uncontrolled hypertension (e.g. systolic pressure \>160 or a diastolic blood pressure \> 100) * Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma * Currently on a weight-loss diet or body mass index \> 30 kg/m2 * Inability to abstain from smoking for duration of study * HIV or hepatitis B or C\* * Subjects excluded due to positive screening results, including HIV, hepatitis B or hepatitis C, will be immediately scheduled for counseling and follow-up testing as needed, and will be advised to consult their primary physician. * Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted). Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted) * Subjects with hemoglobin or hematocrit lower than accepted lab values * History of stroke with motor disability * A recent history (\<12 months) of GI bleed * Depression \[\>5 on the 15 items Geriatric Depression Scale (GDS)\]\* \*This criteria will only apply to subjects in the bed rest arm. * Liver disease (the ratio of serum aspartate aminotransferase to serum alanine aminotransferase 2 times above the normal limit, hyperbilirubinemia) History of respiratory disease * Currently taking estrogen products (topical vaginal products are not exclusionary (e.g. cream)) * Recent travel history as defined by 4 hours of travel by airplane in the last week * Any other condition or event considered exclusionary by the PI and faculty physician
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Insulin resistance are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Utah
Salt Lake City, Utah, 84108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Muscle disease may confuse heart attack tests: study aims to clarify
- COVID-19's hidden toll: muscle wasting in the ICU
- Insulin may quiet the immune alarm tied to heart disease
- Can weightlifting beat cardio for blood sugar in pregnancy?
- Strawberries as medicine? trial tests whether the fruit can calm inflammation and boost insulin response
- Can cutting carbs curb metabolic syndrome in teens?